Objective Systemic lupus erythematosus (SLE) is associated with increased susceptibility to infections, including herpes ...
Editor’s note: This round‑up is based on press releases, peer‑reviewed publications, and company communications received in January and February 2026. All results are preliminary unless stated, and ...
Background Although the increased risk of cardiovascular disease in patients with SLE is well-documented, effective tools for risk stratification remain elusive. This study sought to explore the ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Subcutaneous anifrolumab improved over placebo in BICLA ...
A new study exploring the investigational therapy, Zorpo-cel, met its primary safety and secondary efficacy endpoints in people with progressive and treatment-resistant systemic sclerosis (SSc), ...
AstraZeneca's new formulation of systemic lupus erythematosus (SLE) therapy Saphnelo has been turned down by the FDA, despite getting the go-ahead in Europe a few weeks ago. The US regulator has ...
There is a simple discount patient access scheme for obinutuzumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact welwyn.rx_bdop ...
University of Virginia third-year student Torrae Bennett has built her UVA experience around serving others. Her passion for advocacy, public health and community-centered design grew out of her ...
UPDATE: Following Congress' passage, the President signed this legislation into law on Feb. 3, 2026. This afternoon, Congress took the final steps in the FY 2026 budget process, passing legislation ...
Help us make Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this resource center more useful to clinicians.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results